Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and sales of the drug, casting doubts on the treatment’s future.